Development

FDA has halted enrollment in clinical studies for Gilead Sciences’ magrolimab, a biologic treatment in development for acute myeloid leukemia.

With this agreement, Chiesi Global Rare Diseases will co-develop drug delivery systems with Aliada Therapeutics for large molecule therapeutics that can cross the blood-brain barrier.

A major grant from the Bill & Melinda Gates Foundation will bolster efforts to fight the global HIV/AIDS epidemic.

Webinar Date/Time: Thu, Sep 14, 2023 11:00 AM EDT

Webinar Date/Time: Tue, Sep 26, 2023 11:00 AM EDT

Webinar Date/Time: Thursday, September 28th, 2023 10:00 AM EDT

Webinar Date/Time: Tuesday, September 12, 2023

Stable producer cell lines show real promise despite continued development challenges.

Webinar Date/Time: Wed, Sep 27, 2023 11:00 AM EDT

Burgeoning CGT modalities bring promise and challenges.

Scale-up strategies for cell culture will require a deep understanding of overall bioprocess workflows.

Advanced analytical tools generate more data in today’s labs than ever before.

mRNA may be a modality whose chief advances are yet to come.

Teva Pharmaceuticals and Alvotech will expand their partnership for the development and commercialization of biosimilar candidates.

Janssen has received a positive opinion from the EMA for two novel bispecific antibodies, TALVEY (talquetamab) and TECVAYLI (teclistamab), which the company is developing to treat blood cancer.

Newly launched Crossbow Therapeutics will work to advance a novel class of antibody therapies for treating cancers.

Webinar Date/Time: Tue, Aug 15, 2023 11:00 AM EDT

Exploring new fields can bring novel antibody candidates to the pipeline.

Camena Bioscience has completed $10 million in Series A financing on the back of growing demand for DNA synthesis.

Thermo Fisher Scientific’s new tumoroid culture medium kit is designed to help cancer researchers better model the disease.

Eurofins Genomics Blue Heron’s novel mRNA synthesis service is designed for customizable applications.

Chime Biologics, Leads Biolabs, and BeiGene have formed a three-way collaboration to advance the development and global manufacturing of Leads Biolabs’ lead mAb candidate, LBL-007.

Despite many development challenges, stable producer cell lines show real promise.

If we view a change opposite of one’s interest as antithetical to innovation, we risk losing sight of our ultimate goal.

Webinar Date/Time: Wed, Jul 19, 2023 11:00 AM EDT